Traders should monitor the AACR 2026 presentations in April for clinical data on muzastotug, particularly safety and response rates in difficult-to-treat cancers. Positive data could catalyze upward movement given Adagene's small market cap ($188M).
Price Chart
Executive Summary
Adagene Inc. announced that its lead candidate, muzastotug (ADG126), will be featured in two poster presentations at the AACR 2026 meeting, showcasing Phase 1b/2 data in advanced colorectal cancer and hepatocellular carcinoma. The presentations will provide clinical updates on the safety and efficacy of muzastotug, a masked anti-CTLA-4 antibody with FDA Fast Track designation, in combination with other therapies.
Key Facts
- Muzastotug (ADG126) will be presented in two poster sessions at AACR 2026 in April 2026.
- Data includes Phase 1b evaluation in combination with pembrolizumab and fruquintinib in metastatic microsatellite stable colorectal cancer.
- Phase 1b/2 Morpheus Liver study results in hepatocellular carcinoma (HCC) will also be presented.
- Muzastotug has FDA Fast Track designation and uses Adagene’s SAFEbody precision masking technology.
- No new clinical results or financial figures were disclosed in this release — only announcement of upcoming presentations.
Financial Impact
No direct financial impact disclosed; potential indirect impact from data readouts in April 2026
Risk Factors
- Clinical data may not meet expectations, especially in MSS-CRC which is historically resistant to immunotherapy.
- No efficacy or safety results are included in this release — only the announcement of upcoming presentations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257692 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $3.20 | awaiting T+60 | — | $2.49 (−22.19%) |
Sep 22, 2026 5w ago | 6-K | $3.23 | awaiting T+60 | — | $2.49 (−22.91%) |
Sep 10, 2026 6w ago | 6-K | $3.31 | awaiting T+60 | — | $2.49 (−24.77%) |
Sep 9, 2026 6w ago | 6-K | $3.27 | awaiting T+60 | — | $2.49 (−23.85%) |
Aug 16, 2026 10w ago | Institutional Cluster | $3.83 | awaiting T+60 | — | $2.49 (−34.99%) |
Aug 12, 2026 10w ago | 6-K | $3.75 | awaiting T+60 | — | $2.49 (−33.60%) |
Aug 12, 2026 10w ago | Press Release | $3.75 | awaiting T+60 | — | $2.49 (−33.60%) |
Jul 6, 2026 16w ago | 6-K | $3.93 $3.21 | ▼ −18.32% | ▼ −20.04% | $2.49 (−36.64%) |
Apr 17, 2026 27w ago | 6-K | $3.89 $3.67 | ▼ −5.66% | ▼ −12.43% | $2.49 (−35.99%) |
Apr 2, 2026 29w ago | 6-K | $3.99 $4.20 | ▼ −5.26% | ▲ +8.90% | $2.49 (+37.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers